Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SH) Latest Company News

Oct 16, 2026, 11:28 UTC
China's National Medical Products Administration approved ponatinib tablets, a 15 mg generic, for Chengdu Shude Pharmaceutical, a wholly owned subsidiary of YD Bio.
Source:
- finance.sina.cn
Oct 8, 2026, 11:17 UTC
China’s National Medical Products Administration approved Yidu Bio’s 0.2 ml:2 mg Vitamin K1 Injection and issued a drug registration certificate; the approval is deemed to satisfy generic drug consistency evaluation requirements.
Source:
- finance.sina.cn
Sep 7, 2026, 09:33 UTC
Yuandong Biologics announced it will repurchase and cancel 257,454 shares of its 2024 employee stock ownership plan that failed to unlock in the second vesting period, at a repurchase price of 21.63 yuan per share, reducing total shares from 176,532,300 to 176,274,800.
Source:
- finance.sina.cn
Aug 31, 2026, 09:29 UTC
Yuandong Biologics announced that as of the end of August 2026, it had repurchased 1,386,528 shares (0.7854% of total share capital) for a total amount of 60.7535 million yuan, within its buyback program running from June 4 to September 3, 2026.
Source:
- finance.sina.cn
Aug 20, 2026, 09:20 UTC
Yuandong Biologics announced its first-half 2026 results: revenue of 659 million yuan, net profit down 4.99% year-on-year.
Source:
- finance.sina.cn
Aug 20, 2026, 09:20 UTC
Yuandong Biological announced the termination of its biological drug research project, with remaining raised funds of 100 million yuan to be permanently used as working capital.
Source:
- finance.sina.cn

688513.SH

China's National Medical Products Administration approved ponatinib tablets, a 15 mg generic, for Chengdu Shude Pharmaceutical, a wholly owned subsidiary of YD Bio.

China’s National Medical Products Administration approved Yidu Bio’s 0.2 ml:2 mg Vitamin K1 Injection and issued a drug registration certificate; the approval is deemed to satisfy generic drug consistency evaluation requirements.

Yuandong Biologics announced it will repurchase and cancel 257,454 shares of its 2024 employee stock ownership plan that failed to unlock in the second vesting period, at a repurchase price of 21.63 yuan per share, reducing total shares from 176,532,300 to 176,274,800.

Yuandong Biologics announced that as of the end of August 2026, it had repurchased 1,386,528 shares (0.7854% of total share capital) for a total amount of 60.7535 million yuan, within its buyback program running from June 4 to September 3, 2026.

Yuandong Biologics announced its first-half 2026 results: revenue of 659 million yuan, net profit down 4.99% year-on-year.

Yuandong Biological announced the termination of its biological drug research project, with remaining raised funds of 100 million yuan to be permanently used as working capital.